title: Clinical significance of telomerase activation and telomeric restriction fragment (TRF) in cervical cancer.
abstract: Telomerase activation was examined in 50 cases of cervical cancer, 27 normal cervix and five cervical cancer cell lines using the sensitive polymerase chain reaction (PCR)-based TRAP (telomeric repeat amplification protocol) assay. Telomeric restriction fragment (TRF) length of these specimens was measured by Southern hybridisation. Telomerase activation was common in cervical cancers and was detected in 46/50 cases (92%). Telomerase activity was weak in normal cervix and was detected only in 2/27 cases (7.4%). Telomerase activity was detected in all stages of cervical cancer suggesting that it is an early event in cancer progression. The clinical significance of telomerase activation was analysed in 47 squamous cell carcinoma of the cervix. High telomerase activity was more frequently detected in advanced diseases (100% in stage III and stage IV cervical cancers combined) compared with early diseases (68.6% in stage I and stage II cancers combined). The difference was statistically significant (P < 0.02). Telomerase activity was not statistically correlated with other clinical parameters examined. This is the first report of telomeric length in human cervical cancer. Both shortening and elongation of TRF length in cervical cancers was observed. Advanced cervical cancers tended to have a wider range of variation of TRF length compared with early disease and normal cervix. There was no obvious relationship between TRF length and the clinical parameters examined including clinical staging, differentiation status of tumour, human papilloma virus (HPV) infection, recurrence rate, tumour size and invasion depth. The clinical significance of TRF length appears to be limited in cervical cancers. Our results indicate that telomerase activity is closely associated with tumour cells and may be useful as a marker for detection of tumour cells in cervical biopsies.
authors.affiliation: Department of Anatomy, Faculty of Medicine, University of Hong Kong, Hong Kong.
authors.forename: D K
authors.initials: DK
authors.lastname: Zhang
authors.forename: H Y
authors.initials: HY
authors.lastname: Ngan
authors.forename: R Y
authors.initials: RY
authors.lastname: Cheng
authors.forename: A N
authors.initials: AN
authors.lastname: Cheung
authors.forename: S S
authors.initials: SS
authors.lastname: Liu
authors.forename: S W
authors.initials: SW
authors.lastname: Tsao
mesh_terms: D000230:Adenocarcinoma / Q000201:enzymology*; D000328:Adult; D000368:Aged; D015139:Blotting, Southern; D002294:Carcinoma, Squamous Cell / Q000201:enzymology*; D005260:Female; D006801:Humans; D008875:Middle Aged; D016133:Polymerase Chain Reaction / Q000379:methods; D019098:Telomerase / Q000378:metabolism*; D016615:Telomere / Q000201:enzymology* / Q000235:genetics; D014407:Tumor Cells, Cultured; D002583:Uterine Cervical Neoplasms / Q000201:enzymology*
chemical_list: D019098:Telomerase